Pharmagreen Biotech Inc. Stock price OTC Markets

Equities

PHBI

US00922N1046

Biotechnology & Medical Research

Delayed OTC Markets 11:11:07 2021-10-05 am EDT 5-day change 1st Jan Change
0.0289 USD -.--% Intraday chart for Pharmagreen Biotech Inc. -4.87% +172.64%
Sales 2022 - Sales 2023 0 Capitalization 401K
Net income 2022 - Net income 2023 - EV / Sales 2022 -
Net Debt 2022 331K Net Debt 2023 372K EV / Sales 2023 257,842,228 x
P/E ratio 2022
-4.61 x
P/E ratio 2023
-0.57 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 87.23%
More Fundamentals * Assessed data
Dynamic Chart
Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Pharmagreen Biotech Inc. cancelled the transaction announced on November 2, 2022 CI
Pharmagreen Starts Sales of MaxGenomicTM Supplement on Amazon.Com and Develops Its Next Pre-Workout Formulation CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022 CI
Pharmagreen Biotech, Inc. Launches Online Sales for Its MaxGenomic(TM) Supplement Product CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2022 CI
Pharmagreen Biotech Inc. Auditor Raises 'Going Concern' Doubt CI
Pharmagreen Biotech Inc. announced that it expects to receive $0.05 million in funding from JanBella Group, LLC CI
Pharmagreen Biotech Inc. Develops a Proprietary Nutraceutical Formulation and Prepares for Product Launch CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022 CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022 CI
Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021 CI
More news
Managers TitleAgeSince
Chief Executive Officer 53 13-12-08
Director of Finance/CFO 77 15-07-21
Chief Tech/Sci/R&D Officer - 22-09-21
Members of the board TitleAgeSince
Chief Executive Officer 53 13-12-08
Director of Finance/CFO 77 15-07-21
More insiders
Pharmagreen Biotech Inc. is a Canada-based integrated cannabis company. The Company's principal business is engaged in the production of starter plantlets for the North American cannabidiol (CBD) hemp and medical cannabis industries through the application of the plant tissue culture in vitro process, Chibafreen. It also provides laboratory-based services to the North American cannabis and agriculture sectors. It is focused on therapeutic plants and fungi, a nutraceutical wellness product. The Company's projects include a Live Rosin Unit, State-of-the-art Greenhouse, a Nursery Unit, Plant Tissue Culture Unit, a Live Plant Storage Unit and a DNA Testing Services Unit. The Company's subsidiaries include WFS Pharmagreen Inc. (WFS) and 1155097 BC Ltd. (115BC).
More about the company
  1. Stock
  2. Equities
  3. Stock Pharmagreen Biotech Inc.
  4. Stock Pharmagreen Biotech Inc. - OTC Markets